Tristel signals boost in first half profits
Infection prevention products manufacturer Tristel said on Tuesday that it expected unaudited pre-tax profit for the first half, before share-based payments, to be at least £2.8m, rising from £2.4m year-on-year.
The AIM-traded firm, which was holding its annual general meeting, said the expected pre-tax profit included a positive contribution from operations in Belgium, the Netherlands, France and Italy, which were all acquired in the past year.
“The company is performing in line with management's expectations, and our United States regulatory approvals project is progressing well,” said chief executive officer Paul Swinney.
Outgoing chairman Paul Barnes also welcomed Dr Bruno Holthof to the new chair position on behalf of the board.
“Our company will undoubtedly benefit from his very broad experience of global healthcare,” Barnes said.
Tristel said its unaudited interim results would be announced on 24 February.
At 0946 GMT, shares in Tristel were up 4.46% at 363p.